JANXJanux Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $10M
- 5.6% YoY
- Operating margin
- -1576.7%
- 69% YoY
- EBITDA
- −$156M
- 61% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired402% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $4M | $9M | $8M | $11M | $10M | 5.6% |
| Operating income | −$33M | −$67M | −$73M | −$99M | −$158M | 60% |
| Net income | −$33M | −$63M | −$58M | −$69M | −$114M | 65% |
| Operating cash flow | −$17M | −$43M | −$51M | −$44M | −$82M | 88% |
| Capex | $1M | $6M | $2M | $359K | $1M | 191% |
| Stock-based comp | $7M | $17M | $20M | $33M | $40M | 22% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $14M | −$18M | 105 | 135 |
| FY2024 | $9M | $55M | 407 | 102 |
| FY2023 | $4M | $1M | 81 | 104 |